Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells

Biochem J. 2002 Dec 1;368(Pt 2):565-72. doi: 10.1042/BJ20020838.

Abstract

Unstimulated PC12 pheochromocytoma cells contain many proteins that bound to 14-3-3s in competition with a 14-3-3-binding peptide. Additional proteins, including one of 39 kDa (p39), became capable of binding to 14-3-3s in phosphatidylinositol 3-kinase-dependent responses to epidermal growth factor or nerve growth factor in vivo. The growth factor regulation was unaffected by inhibitors of the mitogen- or stress-activated protein kinase pathways, or by glucose starvation, but was blocked by amino acid starvation and only partially blocked by rapamycin. p39 in extracts of unstimulated, nutrient-fed cells, but not nutrient-starved cells, was able to bind to 14-3-3s after phosphorylation by protein kinase B (PKB) in vitro. Nutrient starvation did not affect the growth factor-stimulated activation of PKB in vivo. Either cycloheximide (CHX) or the cysteine protease inhibitor, MG132, restored the responsiveness of p39 to growth factors in nutrient-starved cells. In contrast, MG132 could not replace amino acids in supporting the growth factor-stimulated phosphorylation of two downstream targets of mTOR (mammalian target of rapamycin), namely eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and p70 S6 kinase. CHX permitted complete growth factor-stimulated phosphorylation of both 4E-BP1 and p70 S6 kinase in nutrient- starved cells; however, unlike p39, phosphorylation of these proteins was blocked by rapamycin. These findings implicate PKB (or an enzyme with similar specificity) in the growth factor-triggered phosphorylation of p39. In addition, amino acid starvation induces a CHX- and MG132-sensitive pathway that targets p39 and appears to be distinct from the mechanism of regulation of 4E-BP1 and p70 S6 kinase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 14-3-3 Proteins
  • Amino Acids / pharmacology*
  • Animals
  • Carrier Proteins / drug effects
  • Carrier Proteins / metabolism
  • Cell Extracts
  • Chromones / pharmacology
  • Cycloheximide / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Epidermal Growth Factor / pharmacology
  • Glucose / pharmacology
  • Growth Substances / pharmacology*
  • Intracellular Signaling Peptides and Proteins
  • Leupeptins / pharmacology
  • Morpholines / pharmacology
  • Nerve Growth Factor / pharmacology
  • PC12 Cells / drug effects
  • PC12 Cells / metabolism
  • Phosphoproteins / drug effects
  • Phosphoproteins / metabolism
  • Phosphorylation
  • Protein Serine-Threonine Kinases*
  • Proteins / drug effects
  • Proteins / metabolism*
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-akt
  • Rats
  • Ribosomal Protein S6 Kinases, 70-kDa / drug effects
  • Ribosomal Protein S6 Kinases, 70-kDa / metabolism
  • Tyrosine 3-Monooxygenase / drug effects
  • Tyrosine 3-Monooxygenase / metabolism*

Substances

  • 14-3-3 Proteins
  • Amino Acids
  • Carrier Proteins
  • Cell Extracts
  • Chromones
  • Eif4ebp1 protein, rat
  • Enzyme Inhibitors
  • Growth Substances
  • Intracellular Signaling Peptides and Proteins
  • Leupeptins
  • Morpholines
  • Phosphoproteins
  • Proteins
  • Proto-Oncogene Proteins
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Epidermal Growth Factor
  • Nerve Growth Factor
  • Cycloheximide
  • Tyrosine 3-Monooxygenase
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Ribosomal Protein S6 Kinases, 70-kDa
  • Glucose
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde